Quick answer
What is CJC-1295 in research terms? A family of synthetic analogs of the first 29 residues of growth-hormone-releasing hormone. “CJC-1295 with DAC” carries an albumin-binding maleimide group and persisted in rat plasma beyond 72 hours; “CJC-1295 without DAC” (modified GRF 1-29, the form V8 lists) has no such group and acts briefly. This sheet collects the names, formulas and published numbers in one place, each with its source, so claims can be checked quickly. For laboratory research use only; not for human consumption.
Most confusion about CJC-1295 is confusion of terms and numbers: two molecules share a name, and figures measured for one are quoted for the other. This reference sheet is built to be scanned. It does not replace the longer articles, but it lets a reader find the right term, number or formula, and the source behind it, in a minute. The full background is in the CJC-1295 No DAC research overview. For laboratory research use only; not for human consumption.
Glossary of names
| Term | Meaning |
|---|---|
| GHRH, GRH, GRF | Growth-hormone-releasing hormone (also called releasing factor), the 44-residue hypothalamic peptide; first isolated from pancreatic tumors in 1982 (Guillemin and colleagues, 1982) |
| GHRH(1-29)-NH2, hGRF(1-29), sermorelin | The 29-residue amidated fragment that retains in vivo activity (Clark and Robinson, 1985) |
| Modified GRF(1-29), mod-GRF, CJC-1295 without DAC | Fragment with protective substitutions (D-Ala2, Gln8, Ala15, Leu27); no albumin anchor |
| CJC-1295, CJC-1295 with DAC | Tetrasubstituted fragment with a C-terminal lysine carrying a maleimidopropionamide group that bonds albumin (Jetté and colleagues, 2005) |
| DAC | Drug affinity complex: the albumin-binding linker |
| GHRH receptor | Pituitary G-protein-coupled receptor cloned in 1992 (Mayo, 1992) |
| GHRHKO | GHRH knockout mouse, a model of isolated GH deficiency (Alba and Salvatori, 2004) |
| IGF-I | Downstream mediator of GH, a slow integrating marker of the axis |
| DPP-IV | Dipeptidyl peptidase IV, which removes N-terminal dipeptides from native GHRH in plasma (Frohman and colleagues, 1986) |
Published numbers, with sources
| Number | What it describes | Source |
|---|---|---|
| 63 min vs 17 min | Half-life of native GRH(1-44)-NH2 in human plasma in vitro, by immunoassay vs HPLC | Frohman and colleagues, 1986 |
| Less than 10−3 | Relative biological activity of the GRH(3-44) cleavage product | Frohman and colleagues, 1986 |
| 4-fold | Increase in GH area under the curve over 2 h for CJC-1295 vs hGRF(1-29) in rats | Jetté and colleagues, 2005 |
| Beyond 72 h | Plasma presence of CJC-1295 (DAC form) in rats | Jetté and colleagues, 2005 |
| 24, 48, 72 h | Exposure intervals compared in GHRHKO mice; every 24 h gave normal body weight and length | Alba and colleagues, 2006 |
| About 60% | Body weight of GHRHKO mice relative to littermates at 12 weeks | Alba and Salvatori, 2004 |
| 1.3 nmol/L | EC50 of ipamorelin for GH release from primary rat pituitary cells | Raun and colleagues, 1998 |
Anything that does not appear in this table has not been verified here. In particular, no primary half-life value for the no-DAC analog is cited on this sheet, because none is in the sources listed.
Properties of the product listed by V8
From the CJC-1295 (No DAC) product page: lyophilized powder in a sealed clear glass vial, 5 mg or 10 mg, formula C152H252N44O42 (about 3,368 g/mol), purity ≥98% by HPLC, storage 2–8 °C with −20 °C for long term, protected from heat, moisture and light. The blend with ipamorelin is on the blend page. Certificates, where published, are in the COA library.
Formulas used in CJC-1295 bench work
| Purpose | Formula |
|---|---|
| Concentration of a reconstituted vial | mg/mL = vial mass (mg) ÷ diluent volume (mL) |
| Diluent volume for a target | volume (mL) = vial mass (mg) ÷ target (mg/mL) |
| Molar concentration | mol/L = (g/L) ÷ molar mass (g/mol) |
| Working dilution | c₁ × V₁ = c₂ × V₂ |
| Half-life from rate constant | t½ = 0.693 ÷ k |
| Percent remaining by HPLC | (peak area at t ÷ peak area at 0) × 100 |
| Purity by area percent | main peak area ÷ total peak area × 100 |
The calculator does the first three, and the arithmetic is explained in reconstitution volume calculations.
Common mix-ups
- DAC versus no DAC. Multi-day plasma presence belongs to the DAC conjugate. The no-DAC analog is short-acting. See DAC versus no DAC.
- Mass versus moles. A 1:1 blend by mass is not 1:1 by molecules.
- Purity versus content. A purity percentage describes the HPLC main peak and not the peptide fraction by weight.
- Immunoassay versus HPLC. An immunoassay can overstate persistence by detecting inactive fragments (63 versus 17 minutes in the native-hormone study).
- Deficiency model versus normal axis. Knockout results describe restoration of a missing signal.
- Pulse versus continuous exposure. In rats pulsatile GRF(1-29)NH2 promoted growth where continuous did not (Clark and Robinson, 1985).
A checklist for reading any CJC-1295 claim
Before repeating a statement about CJC-1295, five questions catch most errors. Which form was studied, DAC or no DAC? In what system: cultured cells, plasma in vitro, a normal animal or a deficiency model? Which species and sex? Which endpoint, measured how and when after the last exposure? And is the number from a primary paper that the writer has read, or from a summary of a summary? Each question has appeared above as a documented source of confusion: the half-life of the native hormone differs by method (63 versus 17 minutes), the knockout results describe restoration of a missing signal, the rat growth result depends on pulsatile pattern, and ipamorelin potency is given in nanomolar units for rat cells.
When writing a methods or background section, cite the primary paper for each number, say which form it concerns, and label inferences as inferences. For the no-DAC compound that means saying plainly that its characterization rests largely on its structure and on related analogs. Reference details for every number on this sheet are in the list below, and the longer articles in this library expand each topic with the same discipline.
Where to read next
| Question | Read |
|---|---|
| What is the compound and its history? | CJC-1295 No DAC research overview |
| How do the two forms differ? | DAC research overview and comparison |
| How is it dissolved and stored? | reconstitution guide and storing research peptides |
| How is purity read? | purity testing and how to read a COA |
| How does it relate to ipamorelin? | CJC-1295 and ipamorelin |
| How does it compare with related analogs? | versus sermorelin and versus tesamorelin |
Frequently asked questions
What does CJC-1295 mean?
It names a family of analogs of GHRH(1-29). The original paper defined CJC-1295 as the albumin-binding form; the no-DAC form is the modified fragment without the linker.
What does DAC stand for?
Drug affinity complex, the maleimide-linked lysine that bonds the peptide to serum albumin.
What is mod-GRF(1-29)?
Another name for CJC-1295 without DAC: GHRH(1-29)-amide with D-Ala2, Gln8, Ala15 and Leu27 substitutions.
What is the molar mass of CJC-1295 (no DAC)?
About 3,368 g/mol, from the formula C152H252N44O42 on the product page.
Which number shows the DAC form is long-lived?
Plasma presence beyond 72 hours in rats, from the primary 2005 report.
Why is native GHRH short-lived?
A plasma dipeptidyl peptidase removes the first two residues. In human plasma in vitro the intact 44-mer had a half-life of 17 minutes by HPLC.
What did the knockout-mouse study compare?
Intervals of 24, 48 and 72 hours between administrations over five weeks. Every 24 hours gave normal body weight and length; the longer intervals were less effective.
How is the vial concentration calculated?
Mass of peptide in the vial divided by volume of diluent added, in mg/mL. The calculator on the site does this.
Is there a published half-life for the no-DAC analog in the sources cited here?
No. It is described as short-acting, but a primary value is not in these sources.
Is this sheet advice for use outside the laboratory?
No. It summarizes published research and product specifications. V8 supplies the peptide for laboratory research use only.
Related reading: CJC-1295 Reconstitution Calculator: Formulas & Tables.
References
- Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-587. doi:10.1126/science.6812220
- Clark RG, Robinson ICAF. Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats. Nature. 1985;314(6008):281-283. doi:10.1038/314281a0
- Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the N terminus. J Clin Invest. 1986;78(4):906-913. doi:10.1172/JCI112679
- Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-1744. doi:10.1210/mend.6.10.1333056
- Alba M, Salvatori R. A mouse with targeted ablation of the growth hormone-releasing hormone gene: a new model of isolated GH deficiency. Endocrinology. 2004;145(9):4134-4143. doi:10.1210/en.2004-0119
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
